We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Fresenius Medical (FMS) for Now
Read MoreHide Full Article
Fresenius Medical Care AG & Co. KGaA( (FMS - Free Report) is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 4.8% year to date against the industry’s decline of 10.9%. The S&P 500 Index has gained 14% in the same time frame.
The company, with a market capitalization of $10.05 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 23.6% in 2024 after declining in the first half of 2023 and an anticipated decline in the second half. FMS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 49.25%.
Image Source: Zacks Investment Research
Key Catalysts
Fresenius Medical provides a wide range of dialysis products in its dialysis and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.
The company offers an extensive array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products. It is focused on further expanding its home dialysis offerings in order to further boost the quality of life for patients and increase their choice of available treatments.
In August, FMS received 510(k) clearance from the FDA for Versi HD with GuideMe Software — the next-generation portable automated peritoneal dialysis system with a completely reinvented self-guided interface. The software can facilitate a smooth and safe switch from hospital to home with easier training experiences. The company has planned to launch the VersiHD with GuideMe Software in selected markets in 2023. Moreover, existing users of VersiHD are also eligible for an upgrade to the GuideMe Software.
Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), the Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. It also aims to align its business activities through public-private partnerships in the dialysis business to tap into new markets in the coming quarters.
FMS exited the second quarter on a decent note. Its results reflected improving treatment volumes as well as a stabilizing labor environment in the United States. A potential continuation of improvement in these two key factors will be beneficial for the company in the rest of 2023. Overall price improvements also supported growth in the Care Enablement segment.
What’s Hurting the Stock?
Fresenius Medical has numerous competitors in the field of health care services and the sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which, in turn, can lead to a loss of market share.
Recently, positive data from a late-stage study evaluating Novo Nordisk’s new diabetes drug, Ozempic, has raised concern about a potential rise in competition for Fresenius Medical. Clinical data suggests that the adoption of Ozempic may have an adverse impact on dialysis of patients — a major source of revenue for FMS — going forward.
A lower volume of dialysis led by a potential delay in chronic kidney disease (due to the use of Ozempic) can be detrimental for Fresenius Medical’s top line. Shares of the company plunged significantly following the announcement of the Ozempic study data last week.
U.S. revenues continued to be hurt by the FX impact. Moreover, the bottom line was hurt by inflationary cost increases in energy, material and personnel. However, FMS’ cost-saving initiatives have helped cushion the decline in operating margin. Meanwhile, planned divestitures, as part of the company’s transformational plan, will lead to a loss of revenues going forward.
Estimate Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $21.39 billion, indicating growth of 4.8% from the previous year’s reported number. The consensus mark for earnings is pinned at $1.29 per share, implying a decline of 21.3% from the year-ago level.
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 35% year to date compared with the industry’s 38% growth.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has gained 18.7% year to date compared with the industry’s 38% growth.
Medpace, carrying a Zacks Rank #2 at present, has an estimated growth rate of 16.2% for 2024. MEDP’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 22.28%.
The company’s shares have rallied 15.9% year to date against the industry’s 12.5% decline.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Here's Why You Should Retain Fresenius Medical (FMS) for Now
Fresenius Medical Care AG & Co. KGaA( (FMS - Free Report) is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 4.8% year to date against the industry’s decline of 10.9%. The S&P 500 Index has gained 14% in the same time frame.
The company, with a market capitalization of $10.05 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 23.6% in 2024 after declining in the first half of 2023 and an anticipated decline in the second half. FMS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 49.25%.
Image Source: Zacks Investment Research
Key Catalysts
Fresenius Medical provides a wide range of dialysis products in its dialysis and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.
The company offers an extensive array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products. It is focused on further expanding its home dialysis offerings in order to further boost the quality of life for patients and increase their choice of available treatments.
In August, FMS received 510(k) clearance from the FDA for Versi HD with GuideMe Software — the next-generation portable automated peritoneal dialysis system with a completely reinvented self-guided interface. The software can facilitate a smooth and safe switch from hospital to home with easier training experiences. The company has planned to launch the VersiHD with GuideMe Software in selected markets in 2023. Moreover, existing users of VersiHD are also eligible for an upgrade to the GuideMe Software.
Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), the Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. It also aims to align its business activities through public-private partnerships in the dialysis business to tap into new markets in the coming quarters.
FMS exited the second quarter on a decent note. Its results reflected improving treatment volumes as well as a stabilizing labor environment in the United States. A potential continuation of improvement in these two key factors will be beneficial for the company in the rest of 2023. Overall price improvements also supported growth in the Care Enablement segment.
What’s Hurting the Stock?
Fresenius Medical has numerous competitors in the field of health care services and the sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which, in turn, can lead to a loss of market share.
Recently, positive data from a late-stage study evaluating Novo Nordisk’s new diabetes drug, Ozempic, has raised concern about a potential rise in competition for Fresenius Medical. Clinical data suggests that the adoption of Ozempic may have an adverse impact on dialysis of patients — a major source of revenue for FMS — going forward.
A lower volume of dialysis led by a potential delay in chronic kidney disease (due to the use of Ozempic) can be detrimental for Fresenius Medical’s top line. Shares of the company plunged significantly following the announcement of the Ozempic study data last week.
U.S. revenues continued to be hurt by the FX impact. Moreover, the bottom line was hurt by inflationary cost increases in energy, material and personnel. However, FMS’ cost-saving initiatives have helped cushion the decline in operating margin. Meanwhile, planned divestitures, as part of the company’s transformational plan, will lead to a loss of revenues going forward.
Estimate Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $21.39 billion, indicating growth of 4.8% from the previous year’s reported number. The consensus mark for earnings is pinned at $1.29 per share, implying a decline of 21.3% from the year-ago level.
Fresenius Medical Care AG & Co. KGaA Price
Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote
Stocks to Consider
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , McKesson Corporation (MCK - Free Report) and Medpace (MEDP - Free Report) .
Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 35% year to date compared with the industry’s 38% growth.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has gained 18.7% year to date compared with the industry’s 38% growth.
Medpace, carrying a Zacks Rank #2 at present, has an estimated growth rate of 16.2% for 2024. MEDP’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 22.28%.
The company’s shares have rallied 15.9% year to date against the industry’s 12.5% decline.